Ondansetron Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron Hydrochloride Dihydrate, the active ingredient in Ondansetron Kabi, is a 5-HT3 receptor antagonist presented as a sterile injectable solution for intravenous use. It treats and prevents nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery in adult and pediatric patients.

GNH USA supplies Ondansetron Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ondansetron Kabi is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting pathways related to several clinical settings. - Chemotherapy‑induced nausea and vomiting: helps prevent and control acute and delayed episodes. - Radiation‑induced nausea and vomiting: reduces incidence of vomiting during and after radiotherapy. - Post‑operative nausea and vomiting: decreases postoperative nausea and vomiting incidence. - Hyper‑emesis gravidarum (off‑label): may be used when conventional therapy fails, under specialist supervision. - Anticipatory nausea: reduces nausea that develops before chemotherapy cycles. - Nausea due to other emetogenic triggers: provides symptomatic relief in various acute settings.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel motility. - Diarrhoea: occasional loose stools. - Fatigue: general tiredness. - Dizziness: transient light‑headedness. - Injection site reactions: erythema or mild pain.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation. - Severe hypersensitivity: anaphylaxis or angio‑edema. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Severe constipation or ileus: bowel obstruction risk. - Neuroleptic malignant‑like reactions: extremely rare neurological events.

Ondansetron Kabi should be used with caution in patients with known cardiac conduction abnormalities, electrolyte imbalances, or hepatic impairment. - Cardiac monitoring: obtain baseline ECG in patients at risk for QT prolongation. - Electrolyte correction: ensure potassium and magnesium levels are within normal range before administration. - Hepatic dosing: adjust dose in moderate to severe hepatic impairment as per clinical guidelines. - Concomitant serotonergic drugs: evaluate risk of serotonin syndrome. - Pregnancy and lactation: use only if benefit outweighs potential risk. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with several medication classes that affect cardiac repolarisation or serotonergic pathways. Major Interactions (Avoid): - Anti‑arrhythmic agents (e.g., amiodarone, quinidine): increase risk of QT prolongation. - Certain antipsychotics (e.g., haloperidol, ziprasidone): additive QT‑prolonging effect. - Macrolide antibiotics (e.g., erythromycin): may enhance QT prolongation. Moderate Interactions (Monitor Closely): - Serotonergic drugs (e.g., SSRIs, tramadol): risk of serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole): may increase ondansetron plasma levels. - CYP2D6 substrates (e.g., codeine): altered metabolism may affect efficacy.